OA11766A - 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino) ethoxy)benzy) thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical. - Google Patents

5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino) ethoxy)benzy) thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical. Download PDF

Info

Publication number
OA11766A
OA11766A OA1200000178A OA1200000178A OA11766A OA 11766 A OA11766 A OA 11766A OA 1200000178 A OA1200000178 A OA 1200000178A OA 1200000178 A OA1200000178 A OA 1200000178A OA 11766 A OA11766 A OA 11766A
Authority
OA
OAPI
Prior art keywords
hydrate
provides
hydrate according
daims
methyl
Prior art date
Application number
OA1200000178A
Other languages
English (en)
Inventor
Paul David James Blackler
David C Lee
Michael John Sasse
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of OA11766A publication Critical patent/OA11766A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
OA1200000178A 1997-12-16 1998-12-14 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino) ethoxy)benzy) thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical. OA11766A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726566.4A GB9726566D0 (en) 1997-12-16 1997-12-16 Novel pharmaceutical

Publications (1)

Publication Number Publication Date
OA11766A true OA11766A (en) 2005-07-19

Family

ID=10823692

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200000178A OA11766A (en) 1997-12-16 1998-12-14 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino) ethoxy)benzy) thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical.

Country Status (35)

Country Link
EP (2) EP1661895A1 (bg)
JP (1) JP2002508373A (bg)
KR (1) KR100549142B1 (bg)
CN (3) CN101302215A (bg)
AP (1) AP1365A (bg)
AR (1) AR017214A1 (bg)
AU (1) AU1967999A (bg)
BG (1) BG64988B1 (bg)
BR (1) BR9813600A (bg)
CA (1) CA2314107A1 (bg)
CO (1) CO4980880A1 (bg)
CZ (1) CZ299965B6 (bg)
DZ (1) DZ2681A1 (bg)
EA (1) EA004260B1 (bg)
EG (1) EG22337A (bg)
GB (1) GB9726566D0 (bg)
HR (1) HRP20000408B1 (bg)
HU (1) HUP0100509A3 (bg)
IL (1) IL136424A (bg)
IN (1) IN192487B (bg)
MA (1) MA26580A1 (bg)
MY (1) MY135612A (bg)
NO (1) NO317254B1 (bg)
OA (1) OA11766A (bg)
PE (1) PE20000058A1 (bg)
PL (1) PL341146A1 (bg)
RS (1) RS50126B (bg)
SA (1) SA99191115B1 (bg)
SK (1) SK286618B6 (bg)
TR (2) TR200001799T2 (bg)
TW (1) TW509690B (bg)
UA (1) UA72198C2 (bg)
UY (2) UY25308A1 (bg)
WO (1) WO1999031095A1 (bg)
ZA (1) ZA9811506B (bg)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6664278B2 (en) 1997-12-16 2003-12-16 Smithkline Beecham P.L.C. Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
GB9726568D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Novel pharmaceutical
GB9909041D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Plc Novel pharmaceutical
OA11873A (en) * 1999-04-23 2006-03-27 Smithkline Beecham Plc Novel pharmaceutical.
TR200103061T2 (tr) 1999-04-23 2002-05-21 Smithkline Beecham P.L.C. Yeni farmasötik madde.
EP1173435B1 (en) * 1999-04-23 2003-07-30 SmithKline Beecham plc Polymorph of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
HUP0300475A3 (en) * 2000-04-25 2004-10-28 Kyorin Seiyaku Kk Novel stable crystal of thiazolidinedione derivative and process for producing the same
GB0014005D0 (en) * 2000-06-08 2000-08-02 Smithkline Beecham Plc Novel pharmaceutical
GB0021784D0 (en) * 2000-09-05 2000-10-18 Smithkline Beecham Plc Novel pharmaceutical
GB0021978D0 (en) * 2000-09-07 2000-10-25 Smithkline Beecham Plc Novel pharmaceutical
MXPA03002580A (es) * 2000-09-26 2003-10-15 Cord Janet I Nuevas formas polimorficas de maleato de 5-(4-(2-(n-metil-n-(2-piridil) amino)etoxi)bencil) tiazolidin-2, 4-diona y proceso para su preparacion.
GB0129876D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
WO2003050112A1 (en) * 2001-12-13 2003-06-19 Smithkline Beecham Plc Toluenesulfonate hydrates of a thiazolidinedione derivative
GB0129872D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB2405403A (en) * 2003-08-29 2005-03-02 Cipla Ltd Rosiglitazone maleate of particular polymorphic forms and methods of preparing rosiglitazone free base
ITMI20041537A1 (it) * 2004-07-28 2004-10-28 Chemi Spa Nuova forma polimorfa del rosiglitazone maleato
CZ298424B6 (cs) * 2005-05-24 2007-09-26 Zentiva, A. S. Zpusob krystalizace rosiglitazonu a jeho derivátuze smesných rozpouštedel
EP2184055A1 (en) 2008-11-07 2010-05-12 LEK Pharmaceuticals d.d. Process for preparing solid dosage forms of rosiglitazone maleate

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE186724T1 (de) * 1987-09-04 1999-12-15 Beecham Group Plc Substituierte thiazolidindionderivate
GB8820389D0 (en) * 1988-08-26 1988-09-28 Beecham Group Plc Novel compounds
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
WO1995021608A1 (en) * 1994-02-10 1995-08-17 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases

Also Published As

Publication number Publication date
EP1661895A1 (en) 2006-05-31
SK286618B6 (sk) 2009-02-05
CN101302215A (zh) 2008-11-12
NO20003069L (no) 2000-06-15
HRP20000408A2 (en) 2000-08-31
SK9172000A3 (en) 2001-01-18
EP1040110A1 (en) 2000-10-04
PL341146A1 (en) 2001-03-26
HRP20000408B1 (en) 2008-04-30
HUP0100509A3 (en) 2002-06-28
CZ299965B6 (cs) 2009-01-07
TW509690B (en) 2002-11-11
CO4980880A1 (es) 2000-11-27
AP1365A (en) 2005-01-26
IL136424A0 (en) 2001-06-14
KR20010033141A (ko) 2001-04-25
EA004260B1 (ru) 2004-02-26
PE20000058A1 (es) 2000-02-26
NO317254B1 (no) 2004-09-27
AU1967999A (en) 1999-07-05
HUP0100509A2 (hu) 2002-05-29
AR017214A1 (es) 2001-08-22
RS50126B (sr) 2009-03-25
EA200000654A1 (ru) 2000-12-25
JP2002508373A (ja) 2002-03-19
DZ2681A1 (fr) 2004-06-20
TR200001799T2 (tr) 2001-01-22
IL136424A (en) 2003-12-10
MA26580A1 (fr) 2004-12-20
CA2314107A1 (en) 1999-06-24
UY25308A1 (es) 1999-07-19
MY135612A (en) 2008-05-30
TR199802625A3 (tr) 1999-10-21
UY25304A1 (es) 2000-12-29
CZ20002204A3 (cs) 2000-11-15
YU36300A (sh) 2004-03-12
CN101381367A (zh) 2009-03-11
GB9726566D0 (en) 1998-02-11
BG64988B1 (bg) 2006-11-30
BG104603A (bg) 2001-03-30
KR100549142B1 (ko) 2006-02-03
NO20003069D0 (no) 2000-06-15
AP2000001831A0 (en) 2000-06-30
UA72198C2 (en) 2005-02-15
SA99191115B1 (ar) 2006-10-11
WO1999031095A1 (en) 1999-06-24
ZA9811506B (en) 2000-11-06
EG22337A (en) 2002-12-31
TR199802625A2 (xx) 1999-10-21
BR9813600A (pt) 2000-10-10
CN1281453A (zh) 2001-01-24
IN192487B (bg) 2004-04-24

Similar Documents

Publication Publication Date Title
US7368574B2 (en) Substituted thiazolidinedione derivative, process for its preparation and its pharmaceutical use
US20070203200A1 (en) 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione, maleic acid salt, hydrate as pharmaceutical
OA11766A (en) 5-Ä4-Ä2-(N-methyl-N-(2-pyridyl)amino) ethoxy)benzy) thiazolidine-2, 4-dione, maleic acid salt, hydrate as pharmaceutical.
US20060189659A1 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2, 4-dione maleic acid salt
US6806280B1 (en) Polymorph of 5-[4-[2-(n-methyl-n(2-pyridyl)amino)ethoxy]benzyl]-thiazolidine-2,4-dione, maleic acid salt
US6664278B2 (en) Hydrate of 5-[4-[2-(N-methyl-N-(2-pyridil)amino)ethoxy]benzyl]thiazolidine-2,4-dione maleic acid salt
US7358366B2 (en) Thiazolidinedione derivative and its use as antidiabetic
AU2755202A (en) Novel pharmaceutical
US20070185167A1 (en) Sodium salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione
US20050107440A1 (en) Rosiglitazone edisylates and their use as antidiabetics
AU770817B2 (en) 5-(4-(2-(N-methyl-N-(2-pyridyl)amino)ethoxy)benzyl) thiazolidine-2,dione,maleic acid salt, hydrate as pharmaceutical
AU774613B2 (en) Hydrate of 5-(4-(2- (N-methyl-N- (2-pyridil)amino) ethoxy)benzyl) thiazolidine-2,4-dione maleic acid salt
EP1448559B1 (en) 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione benzenesulfonate; process for its preparation; polymorphs i, ii and iii thereof; and its use as pharmaceutical active ingredient
US20040038968A1 (en) Thiazolidinedione derivative and its use as antidiabetic
US20030162815A1 (en) Thiazolidinedione salt for treatment of diabetes mellitus
AU2005229688A1 (en) Tartrate salts of thiazolidinedione derivative